Navigation Links
Pitt pharmacologists go on a molecular fishing trip and hook prize catch
Date:5/2/2010

PITTSBURGH, May 2 Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

There is strong evidence that eating foods rich in omega-3 fatty acids, such as some fish, plant-derived oils and nuts, or taking omega-3s as a dietary supplement reduces inflammation and lowers the risk of illness and death from cardiovascular and other inflammatory diseases, said Bruce A. Freeman, Ph.D., professor and chair of the Department of Pharmacology and Chemical Biology, Pitt School of Medicine, and one of the study's senior authors.

"What has been a provocative question for people familiar with these impressive clinical actions is how omega-3 fatty acids actually induce such beneficial pharmacological effects," he said. "This study has given us fresh and revealing perspective into that process."

In this study, also led by Pitt assistant professor Francisco J. Schopfer, Ph.D., the researchers examined metabolic byproducts of omega-3 fatty acids that are produced by activated macrophages, a type of immune cell that is always present in inflamed tissue, and discovered previously unknown biochemical mediators of inflammation.

Using a small molecule called beta-mercaptoethanol (BME) as a reactive bait, Chiara Cipollina, Ph.D., one of the study's lead authors and a post-doctoral student from Palermo, Italy's Ri.MED Foundation, "hooked" several derivatives of omega-3 fatty acids that were produced by immune cells. These derivatives were chemically modified to become electrophilic fatty acid oxidation products (EFOX), meaning they are attracted to electrons and therefore react with critical molecular targets in many different cell types.

By interacting with certain protein residues that have electrons available for chemical binding, these derivatives stimulate changes in cellular protein function and the genetic expression patterns of cells, resulting in a broad range of antioxidant and anti-inflammatory responses.

The research team found that an enzyme called cyclooxygenase-2 (COX-2), which is the molecular target of common drugs such as aspirin, ibuprofen and acetaminophen, mediates the transformation of omega-3 fatty acids into EFOX. Notably, cellular EFOX concentrations were significantly increased in the presence of aspirin, suggesting another mechanism for that drug's beneficial effects.

"There is a lot of evidence that supports minimizing inflammation as a fundamental therapy for many diseases," Dr. Freeman said. "Our new insights help explain in part the multitude of beneficial actions observed for both omega-3 fatty acids and aspirin, and the discovery of this new class of omega-3 fatty acid-derived anti-inflammatory mediators could point drug development activities in new and fruitful directions."

For example, drugs that, like aspirin, enhance the production of EFOX could be of value, or new agents might be synthesized that are able to induce anti-inflammatory signals that are similar to those induced by EFOX, he explained. Drs. Freeman and Schopfer and their drug discovery team now are working on some of these approaches.


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. New tool helps scientists see molecular signals of eye disease before symptoms arise
2. Lollipops and ice fishing: Molecular rulers used to probe nanopores
3. UT Southwestern researchers identify key molecular step to fighting off viruses
4. Scientists sever molecular signals that prolific parasite uses to puppeteer cells
5. Research pinpoints action of protein linked to key molecular switch
6. Identifying molecular targets for diabetes-related ED
7. Molecular study could push back angiosperm origins
8. U-M researchers solve a molecular mystery in muscle
9. 2010 Yeast Genetics and Molecular Biology Meeting
10. Transforming skin cells into stem cells using a molecular toolkit
11. Scientists discover molecular pathway for organ tissue regeneration and repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), ... for its second quarter ended December 31, 2015. ... quarter of fiscal 2016 increased 2 percent compared to the comparable ... quarter of fiscal 2016 was $35.0 million, or $0.93 per diluted ... net income for the first quarter of fiscal 2016 grew 9 ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... MONMOUTH JUNCTION, N.J. , Feb. 4, 2016 ... critical care immunotherapy leader commercializing its flagship CytoSorb® ... and cardiac surgery patients around the world, announced ... PhD, will present at the Source Capital Group,s ... overview and update on the company.  ...
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
Breaking Biology Technology: